Liposarcoma
Prepared with OnCo (onco.cc/prep/liposarcoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
15 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example MDM2 and CDK4 amplification, FUS-DDIT3 fusion, Round cell component, Grade and site), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (well-differentiated, limb), which of the standard options do you recommend and why?
- 6.For my situation (retroperitoneal well- and dedifferentiated), which of the standard options do you recommend and why?
- 7.For my situation (myxoid liposarcoma), which of the standard options do you recommend and why?
- 8.Am I a candidate for Trabectedin, and what side effects should I expect?
- 9.For my situation (advanced disease), which of the standard options do you recommend and why?
- 10.Am I a candidate for Doxorubicin, Eribulin, Trabectedin, and what side effects should I expect?
- 11.Are there clinical trials I could join, for example of MDM2 inhibitors, Eribulin?
- 12.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 13.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 14.I read that “Retroperitoneal dedifferentiated disease recurs in most patients despite complete surgery”. How does that affect my plan?
- 15.I read that “MDM2 inhibitors cause low platelets that limit dosing”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: MDM2 and CDK4 amplification (FISH; separates from lipoma), FUS-DDIT3 fusion (myxoid), Round cell component (myxoid prognosis), Grade and site (retroperitoneal versus limb).
Scans and tests linked to this cancer: Methylation classifier for sarcomas.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Well-differentiated, limb: Marginal excision; no radiotherapy or systemic therapy; surveillance for local recurrence. (Sarcomas (soft tissue, bone, GIST))
- Retroperitoneal well- and dedifferentiated: Complete en bloc resection in a sarcoma centre; preoperative radiotherapy not routine after STRASS; repeat surgery for recurrence. (Sarcomas (soft tissue, bone, GIST), IMRT / IGRT (modern external beam))
- Myxoid liposarcoma: Surgery with preoperative radiotherapy (highly radiosensitive); trabectedin for advanced disease. (IMRT / IGRT (modern external beam), Trabectedin)
- Advanced disease: Doxorubicin-based chemotherapy, eribulin (overall survival benefit in liposarcoma), trabectedin; MDM2 and CDK4 inhibitors in trials for amplified tumours. (Doxorubicin, Eribulin, Trabectedin, MDM2)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.